ongoing

HD PCI is a multicenter, international, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing percutaneous coronary intervention (PCI) for non-ST elevation acute coronary syndrome (NSTEACS) or stable angina.

The objectives are:

  • To determine if higher dose heparin reduces the composite of death, myocardial infarction (MI) or target vessel revascularization (TVR) compared to lower dose heparin in patients undergoing PCI for NSTEACS or stable angina
  • To determine if lower dose heparin reduces serious bleeding, as measured by the need for blood transfusion after PCI
  • To determine if higher dose heparin improves the net benefit outcome of death, MI, TVR or need for blood transfusion.
Download Presentation PDF
Study Type

Interventional - Drug

Study Design

Randomized registry-based cluster crossover

NO. of Countries

1

NO. of Sites

20 target

NO. of Participants

15366 target

Study Period

2020 - 2022

Sponsor

PHRI

PHRI (internal grant)

Back To Top